Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020

The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out in China. This study aimed to provide insights on the future direction of drug development in PC, thus supplying essential supportive data for stakeholders, including researchers, patients, investors, clinicians, and pharmaceutical industry. The details of the clinical trials of drug therapies for PC during January 1, 2010, to January 1, 2020, were collected from Pharmaprojects. A total of 463 clinical trials on different therapies with 132 different drugs were completed. The long-acting endocrine therapy with few side effects, radiotherapy combined with immune checkpoint inhibitors, gene-targeted chemotherapeutics, and novel immunotherapeutic products changed the concept of PC treatment. In mainland China, 31 trials with 19 drugs have been completed in the 10 assessment years. China has initiated a few trials investigating a limited number of drug targets, centered in a markedly uneven geographical distribution of leading clinical trial units; hence, the development of PC drugs has a long way to go. Given the large patient pool, China deserves widespread attention for PC drug research and development. These findings might have a significant impact on scientific research and industrial investment.

Correction: Endoplasmic reticulum targeted chemotherapeutics: the remarkable photo-cytotoxicity of an oxovanadium(iv) vitamin-B6 complex in visible light

Correction for ‘Endoplasmic reticulum targeted chemotherapeutics: the remarkable photo-cytotoxicity of an oxovanadium(iv) vitamin-B6 complex in visible light’ by Samya Banerjee et al., Chem. Commun., 2014, 50, 5590–5592.

Optical oxygen sensing with quantum dot conjugates

The ability to track and quantify changes in oxygen concentration as a function of disease progression or therapy is crucial to advance targeted chemotherapeutics. New non-invasive sensors must be developed that are small enough to penetrate into tissue and monitor dynamic changes with high resolution in real time. One way to address this challenge is with the use of nanoparticle-based sensors. This review details the design, synthesis, and characterization of optical oxygen sensors that combine a fluorescent semiconductor quantum dot (QD) with an oxygen-responsive phosphorescent molecule. The QD may have multifaceted roles in these constructs, serving as an internal standard for ratiometric sensing, as an antenna for multiphoton absorption, and as an energy transfer donor for the attendant phosphorescent molecule. Solid-state devices may be prepared by embedding the two components in a polymer matrix. Alternatively, solution-phase sensors can be synthesized by covalent conjugation, self-assembly in organic solvents, or micelle encapsulation in aqueous media. Several sensors have been used for biological imaging and oxygen sensing, demonstrating that these constructs can quantify oxygen in biological systems.